AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems
This article was originally published in The Pink Sheet Daily
FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.
You may also be interested in...
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.